滚动资讯
FierceBiotechWith 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'Endpoints NewsEuropean VC Jeito gets $1.2B to help private biotechs control their 'destiny'Endpoints NewsDid Eli Lilly just strike another gold mine?Endpoints NewsWhat’s familiar in health tech’s Q1 funding totalsEndpoints NewsStudy suggests $35 monthly insulin cap has increased patient accessPromega BlogNew Study Suggests Cancer Research Has an Age ProblemEndpoints NewsWhite House adds AbbVie's Humira to TrumpRx alongside cheaper biosimilarsBioPharma DiveTerns rebuffed a higher bid before selling to MerckFierceBiotechLilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinicFierceBiotechLongtime Hologic CEO Steve MacMillan to retire as $18.3B deal closesFierceBiotechOwlet CEO exits suddenly, co-founder returns to the nestFierceBiotechE2 lands $80M series C for next gen thrombectomy treatment
Roche Media 2026年1月27日

罗氏是否正成为肥胖药物市场的有力竞争者？- 医疗数字

罗氏是否正成为肥胖药物市场的有力竞争者？- 医疗数字

原文
暂时没有全文，请查看原始来源。

目录

59 全部